Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
M
MAP
vs
S
S&P/ASX 300
Over the past 12 months, MAP has underperformed S&P/ASX 300, delivering a return of -44% compared to S&P/ASX 300's 4% drop.
Stocks Performance
MAP vs S&P/ASX 300
Performance Gap
MAP vs S&P/ASX 300
Performance By Year
MAP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Microba Life Sciences Ltd
Glance View
Microba Life Sciences is an Australian life sciences company focused on the human gut microbiome. It uses DNA sequencing to analyze microbes in stool samples and turns that data into lab reports, clinical tests, and research tools. Its core products are microbiome testing services for consumers and doctors, plus analysis services used in medical research and drug development. Its main customers are people looking for gut health insights, healthcare professionals, hospitals, researchers, and pharmaceutical or biotech companies that need microbiome data. The company makes money by selling test kits and laboratory analysis, and by charging for research projects, partnerships, and other service work tied to its sequencing platform. What makes Microba different is that it sits at the point where diagnostics and microbiome research meet. Instead of using older culture-based methods, it profiles the full microbial community with sequencing, which lets it identify a much broader set of organisms and support both clinical decisions and drug discovery work.